Introduction {#Sec1}
============

Down syndrome (DS), also known as trisomy 21 syndrome, is the most common chromosomal abnormality, with incidence of 1 in 1000 to 1 in 700 live births^[@CR1],[@CR2]^. DS patients have characteristic facial features, such as wide eye distance, low bridge of nose, eyelid cleft and so on, which are often manifested as moderate to severe inherited intellectual disability and abnormal growth and development^[@CR2]^. Down syndrome usually has multiple system complications^[@CR3]^, causing serious mental and economic burden to the family and society. At present, there is no effective treatment for Down syndrome, which can effectively reduce the birth rate of Down syndrome. It is mainly to find pregnancies considered to be at high risk as determined by prenatal aneuploidy screening. Providing high risk pregnancies prenatal diagnosis, the analysis of fetus chromosome collected via amniocentesis or chorionic villus sampling^[@CR4],[@CR5]^.

When serum biochemical screening was introduced in the China, a hybrid approach was implemented in which amniocentesis was offered to all patients ≥35 years old and to patients \<35 years old who were at increased risk based on the maternal serum markers available at that time. Over time, the screening has evolved by using double screening, triple screening, quadruple screening, CFTS, integrated screening and sequential screening. The efficiency of screening tests are related to the screening strategies, which can vary with the number of biochemical makers, the timing of screening, cut-off value and positive detection rate that we set. Different countries and regions adopt different screening strategies.

In the past decade, NIPS based on massively parallel genomic sequencing (MPS) technology has been widely applied for the clinical detection of trisomy 21, trisomy 18, and trisomy 13^[@CR6]^. A plenty of researches have indicated the excellent performance of NIPS in fetal Down syndrome screening^[@CR7]--[@CR10]^. While NIPS as first-line screening has been suggested, but it was too expensive to be popularized in developing countries. Recent studies show that a contingent strategy was more cost-effective, in which a high risk group is identified through traditional screening methods and only pregnancies in this group are offered NIPS screening^[@CR11]--[@CR17]^. Contingent screening has the potential to reduce invasive diagnostic test and to increase the detection rate of fetal Down syndrome, depending on the different traditional screening risk cut-offs^[@CR18]--[@CR20]^. In developing countries, there are only a few retrospective studies of large samples to explore the combinations of traditional screening and NIPS and to compare which strategy is the most suitable first-line traditional screening test approach to NIPS.

Complicating matters further, traditional screening tests used vary significantly in developing country, such as China. In this study, we evaluated various screening models with different cut-offs to determine the best strategy for implementing contingent screening, considering with their clinical performance and cost.

Results {#Sec2}
=======

Pregnancy characteristics of women with known outcomes are summarized in Table [1](#Tab1){ref-type="table"}. There were 33, 11, 13, 60 cases of trisomy 21 in combined first-trimester screening, quadruple screening, triple screening and double screening, respectively. The incidence of Down syndrome were 1/658,1/735,1/1053,1/1141 in combined first-trimester screening, quadruple screening, triple screening and double screening, respectively.Table 1Pregnancy characteristics of women with four traditional screening tests.CharacteristicCFTSquadruple screeningtriple screeningdouble screening**Number**2171380871369268512**Age distribution**Maternal age at expected date of delivery \<35 years(%)21358(98.37%)7953(98.34%)13500(98.6%)67853(99.04%)Maternal age at expected date of delivery ≥35 years(%)355(1.63%)134(1.66%)192(1.4%)659(0.96%)Maternal age (years) at expected date of delivery (IQR)29.91(27.97--29.91)29.31(27.11--31.88)26.55(23.97--29.2)26.64(24.03--29.19)**Method of conception (%)**Spontaneous20594(94.85%)7831(96.83%)13651(99.7%)68270(99.65%)Assisted1119(5.15%)256(3.17%)41(0.3%)242(0.35%)**Median maternal weight (IQR)**53(49--58)54.5(50--60)53.5(49--59)54(49--59.5)**Median gestational age (days) at blood sample (IQR)**85(85--91)115(112--120)122(116--129)120(115--127)**Insulin-dependent diabetes (%)**14(0.06%)6(0.07%)8(0.06%)42(0.06%)**Smoker (%)**160(0.74%)56(0.69%)25(0.18%)69(0.1%)**Incidence of Down syndrome(‰)**33(1.52,1/658)11(1.36,1/735)13(0.95,1/1053)60(0.88,1/1141)\*Data are given as median (interquartile range) or n (%). IQR, interquartile range.

Performance of traditional screening {#Sec3}
------------------------------------

The number of patients who reached the three group of the risk based on the screening tests used is shown in Table [2](#Tab2){ref-type="table"}. Following combined first-trimester screening, 370 (1.7%), 732 (3.37%) and 20611(94.92%) patients were classified as high risk, intermediate risk and low risk, respectively. Following quadruple screening, 306(3.78%), 598 (7.39%) and 7183(88.82%) patients were classified as high risk, intermediate risk and low risk, respectively. Following triple screening, 415(3.03%), 943(6.89%) and 12334(90.08%) patients were classified as high risk, intermediate risk and low risk, respectively. Following double screening, 3629 (5.3%), 7753 (11.32%) and 57130(83.39%) patients were classified as high risk, intermediate risk and low risk, respectively. Comparing the proportion of high, intermediate, low risk among the four screening tests, the difference is statistically significant (*P* \< 0.01). The combined first-trimester screening had the lowest proportion of high risk and intermediate risk, followed by triple screening, quadruple screening and double screening.Table 2Performance of traditional screening.Risk stratificationCFTSquadruple screeningtriple screeningdouble screeningn(%)T21(%)n(%)T21(%)n(%)T21(%)n(%)T21(%)high risk (risk ≥ 1/270)370 (1.70%)26 (78.79%)306 (3.78%)8 (72.73%)415 (3.03%)9 (69.23%)3629 (5.30%)42 (70.00%)intermediate risk (1/1000 ≤ risk \< 1/270)732 (3.37%)3 (9.09%)598 (7.39%)2 (18.18%)943 (6.89%)2 (15.38%)7753 (11.32%)13 (21.67%)low risk (risk \< 1/1000)20611 (94.92%)4 (12.12%)7183 (88.82%)1 (9.09%)12334 (90.08%)2 (15.38%)57130 (83.39%)5 (8.33%)

The high risk detection rate of combined first-trimester screening was 78.79% (26 out of 33 cases), while that for quadruple screening, triple screening and double screening was 72.73% (8 out of 11 cases), 69.23% (9 out of 13 cases) and 70.00% (42 out of 60 case), respectively. There was no significant difference in the detection rate between the four methods (*P* = 0.829). Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}.Table 3Evaluation index of traditional screening.indexCFTSquadruple screeningtriple screeningdouble screeningTPR(%)78.7972.7369.2370.00TNR(%)98.4196.3197.0994.76FPR(%)1.593.692.915.24PPV(%)7.032.612.171.16\*TPR, true positive rate, also known as detection rate. TNR, true negative rate. FPR, false positive rate. PPV, positive predictive value.

With high risk cut-off of 1:270, the true negative rate of combined first-trimester screening, quadruple screening, triple screening and double screening were 98.41%(21336 out of 21680 cases), 96.31% (7778 out of 8076 cases), 97.09% (13543 out of 13949 cases), 94.76% (64865 out of 68452 cases), respectively. The false positive rates of combined first-trimester screening, quadruple screening, triple screening and double screening were 1.59%(344 out of 21680 cases), 3.69% (298 out of 8076 cases), 2.91% (406 out of 13949 cases), 5.24% (3587 out of 68452 cases), respectively. The positive predictive value of combined first-trimester screening, quadruple screening, triple screening and double screening were 7.03%(26 out of 370 cases), 2.61% (8 out of 306 cases), 2.17% (9 out of 415 cases), 1.16% (42 out of 3629 cases), respectively. And there were significant difference in the true negative rate, false positive rates and positive predictive value between the four methods (*P* \< 0.01).

Cost {#Sec4}
----

Costs and diagnoses of the contingent models are shown in Table [4](#Tab4){ref-type="table"}. When high risk cut-off was 1:50 and intermediate risk cut-off was 1:1000, the overall cost of quadruple screening, triple screening and double screening were all the lowest at their group, they were 892677USD, 1352854 USD, 6728175 USD, respectively. The overall cost of combined first-trimester screening was the lowest (1976253USD) when high risk cut-off was 1:50 and intermediate risk cut-off was 1:1500. For combined first-trimester screening, the cost of contingent models ranged from 1976253USD (detection rate 93.94%, intermediate risk 1:51\~1:1500) to 2173069USD (detection rate 87.88%, intermediate risk 1:271\~1:1000). For quadruple screening, the cost of contingent models ranged from 892677USD (intermediate risk 1:51\~1:1000) to 1111788USD (intermediate risk 1:271\~1:2000) at detection rate of 90.91%. For triple screening, the cost of contingent models ranged from 1352854USD (intermediate risk 1:51\~1:1000) to 1693233USD (intermediate risk 1:271\~1:2000) at detection rate of 84.62%. And for double screening, the cost of contingent models ranged from 6728175USD (detection rate 91.67%, intermediate risk 1:51\~1:1000) to 9167493USD (detection rate 98.33%, intermediate risk 1:51\~1:2000).Table 4Costs of the contingent models.1/1000 ≤ intermediate risk \< 1/50cFTSquadruple screeningtriple screeningdouble screeningn or %USDn or %USDn or %USDn or %USDDR of T21(%)87.8890.9184.6291.67diagnosis1244774063242556826180590227150NIPS9833627278453118051296478224108464002174missed detection for T214738460118461523692305923075screening217131020511808737200213692479220685121575776overall cost216943889267713528546728175average cost per DS detected7480889268122987122330**1/1500** ≤ **intermediate risk** \< **1/50**DR of T21(%)93.9490.9184.6291.67diagnosis1264851065250257127335612235620NIPS145853800211464228741781657189151695597361missed detection for T212369230118461523692303553845screening217131020511808737200213692479220685121575776overall cost1976253100451615329747962602average cost per DS detected63750100452139361139695**1/2000** ≤ **intermediate risk** \< **1/50**DR of T21(%)93.9490.9184.6298.33diagnosis1284928066254107328105633243705NIPS189870036214265261942200811800194137163397missed detection for T212369230118461523692301184615screening217131020511808737200213692479220685121575776overall cost2139383110822116883559167493average cost per DS detected69012110822153487155381**1/1000** ≤ **intermediate risk** \< **1/100**DR of T21(%)87.8890.9184.6291.67diagnosis1907315012949665155596751455560175NIPS917338373779287451120944612199773681513missed detection for T214738460118461523692305923075screening217131020511808737200213692479220685121575776overall cost217049489373313542466740539average cost per DS detected7484589373123113122555**1/1500** ≤ **intermediate risk** \< **1/100**DR of T21(%)93.9490.9184.6291.67diagnosis1927392013050050157604451477568645NIPS139251364810803985201694625086143005276700missed detection for T212369230118461523692303553845screening217131020511808737200213692479220685121575776overall cost1977309100518715339817974966average cost per DS detected63784100519139453139912**1/2000** ≤ **intermediate risk** \< **1/100**DR of T21(%)93.9490.9184.6298.33diagnosis1947469013250820160616001496575960NIPS183267600813605018402113779697182746743106missed detection for T212369230118461523692301184615screening217131020511808737200213692479220685121575776overall cost2140439110927716897479079457average cost per DS detected69046110928153613153889**1/1000** ≤ **intermediate risk** **\<** **1/270**DR of T21(%)87.8890.9184.6291.67diagnosis37414399030911896542016170036681412180NIPS73227010859822066294334796777532860857missed detection for T214738460118461523692305923075screening217131020511808737200213692479220685121575776overall cost217306989624413581176771888average cost per DS detected7493389624123465123125**1/1500** ≤ **intermediate risk** \< **1/270**DR of T21(%)93.9490.9184.6291.67diagnosis37614476031011935042216247036891420265NIPS12074453838993317311428526932120764456044missed detection for T212369230118461523692303553845screening217131020511808737200213692479220685121575776overall cost1979884100769815378528005930average cost per DS detected63867100770139805140455**1/2000** ≤ **intermediate risk** \< **1/270**DR of T21(%)93.9490.9184.6298.33diagnosis37814553031212012042416324037091427965NIPS164760774311794350511847681543160505922450missed detection for T212369230118461523692301184615screening217131020511808737200213692479220685121575776overall cost2143014111178816932339110806average cost per DS detected69129111179153930154420\*The screening results were calculated independently.

Accordingly, When high risk cut-off was 1:50 and intermediate risk cut-off was 1:1000, average cost per DS detected of quadruple screening, triple screening and double screening were all the lowest at their group, they were 89268USD, 122987USD, 122330USD, respectively. The average cost per DS detected of combined first-trimester screening was the lowest (63750USD) when high risk cut-off was 1:50 and intermediate risk cut-off was 1:1500. For combined first-trimester screening, the average cost per DS detected of contingent models ranged from 63750USD (detection rate 93.94%, intermediate risk 1:51\~1:1500) to 74933USD (detection rate 87.88%, intermediate risk 1:271\~1:1000). For quadruple screening, the average cost per DS detected of contingent models ranged from 89268USD (intermediate risk 1:51\~1:1000) to 111179USD (intermediate risk 1:271\~1:2000) at detection rate of 90.91%. For triple screening, the average cost per DS detected of contingent models ranged from 122987USD (intermediate risk 1:51\~1:1000) to 153930USD (intermediate risk 1:271\~1:2000) at detection rate of 84.62%. And for double screening, the average cost per DS detected of contingent models ranged from 122330USD (detection rate 91.67%, intermediate risk 1:51\~1:1000) to 155381USD (detection rate 98.33%, intermediate risk 1:51\~1:2000).

Discussion {#Sec5}
==========

Our study presents that because of the lowest proportion (1.7%) of high risk (cut-off 1:270) with the highest detection rate (78.79%) and the highest positive predictive value (7.03%), the performance of combined first-trimester screening is better than second trimester screening tests. Offering combined first-trimester screening led to the lowest number of invasive tests compared with other traditional screenings. And this consequence is consistent with Lan's research report^[@CR21]^. It is also an advantageous to offer combined first-trimester screening to reduce the risk of iatrogenic fetal loss. Influenced by economic situation, educational background and regional health level, pregnant women have low compliance with the second screening in integrated screening or sequential screening and most pregnant women have received only one traditional screening test in China. If only one traditional screening test is allowed to screen pregnant women regardless of first trimester or second trimester, combined first-trimester screening is recommended as the first choice.

According to Technical standards of prenatal screening and diagnosis for fetal common chromosomal abnormalities and open neural tube defects Part1 Maternal serum prenatal screening in second trimester (the Health Standards of the People's Republic of China, 2010) and Technical Specification for Prenatal Screening and Diagnosis of NIPS (National Health Commission of the People's Republic of China, 2016), women with advanced maternal age were offered the options of amniocentesis and other women received traditional screening as the first-line tests. According to the results of first-line screening, women with the high risk (≥1:270) were offered the options of amniocentesis, women with an intermediate risk (1:1000\~1:271) were offered NIPS and those with a low risk (1:1000) were reassured that fetal trisomies were unlikely and no further testing was necessary. Using this strategy, our study shows contingent model that NIPS contingent on result of combined first-trimester screening has a higher detection rate compared with the second trimester screening tests. And this contingent model can reduce subsequent the number of NIPS, thus reducing the cost of health economics.

The cut-off value of traditional screening needs to consider detection rate, invasive prenatal diagnosis rate and health economic costs and cut-off values of traditional screening in different countries and regions are different. However, with the contingent strategy of traditional screening and NIPS, a more appropriate cut-off should be found. In a study by Gil *et al*., the authors suggested that NIPS could be offered as a contingent screen following combined first trimester screening results. They proposed that women with intermediate risk (defined as 1:11--2500 in that study) could also be offered NIPS^[@CR22]^. Some researchers suggested that the introduction of NIPS as a second line screening test, conditional to a risk ≥1:1000 from Standard of Care screening, showed a 3% increase in the detection of trisomies, with a 71% decrease in the number of invasive tests performed^[@CR23]^. Other previous study suggest that the use of risk scores between 1:251 and 1:1000 may be a more cost-effective threshold^[@CR24]^. While international experience provides some insights, it is very difficult to forecast how the availability and accessibility of NIPS will affect screening for fetal Down syndrome in China, particularly across models with varied definitions of high and intermediate risk.

When adopting quadruple screening or triple screening or double screening as the first-line screening, with high risk cut-off was 1:50 and intermediate risk cut-off was 1:1000, the proportion of women receiving prenatal diagnosis and NIPS were smaller than other cut-off models. For the second trimester screening tests, after adjusting the different risks, with the increase number of invasive diagnostic test and NIPS, the detection rate increases with the increase of cost. The overall cost and average cost per DS detected of combined first-trimester screening as a first-line screening were both the lowest when intermediate risk defined as 1:51\~1500. Moreover, the detection rate of 93.94% remained higher than other cut-off models of combined first-trimester screening. Using this intermediate risk of combined first-trimester screening, the number of missed cases, the number of prenatal diagnosis and NIPS were relatively lower.

The cost of these models is sensitive to variation in uptake in invasive testing and NIPS. The high risk cut-off and intermediate risk cut-off used in the contingent models both had an impact on overall cost and effectiveness. It is helpful to compare economic evaluations on different contingent screening models, costs and assumptions. Consequently, our study found that contingent screening with different cut-offs could offer more cost-effective models, which is consistent with international studies in Belgium, the Netherlands and the UK^[@CR25]--[@CR27]^. In line with the Italian report, we consider that contingent screening using conventional CFTS and second trimester screening tests is effective^[@CR28]^. The cost of each policy as a function of Down syndrome case diagnosed seems the best criterion to substantiate this hypothesis: CFTS is the best policy for the selection of patients to provide NIPS.

Conclusions {#Sec6}
===========

We describe the performance of contingent screening models using a range of increasingly sensitive traditional screening risk cut-offs from the retrospective of the Southwestern China public health system. Our study demonstrated if only one traditional screening test is allowed to screen pregnant women, combined first-trimester screening is recommended as the first choice. The combined first-trimester screening can reduce subsequent the number of NIPS, thus reducing the cost of health economics. The findings of the present study confirm that NIPS contingent on the results of combined first-trimester screening with intermediate risk of 1:51\~1:1500 is a cost-effective means of screening model for fetal Down syndrome in Chinese populations.

To the best of our knowledge, the present study is the first in China to assess the combinations of traditional screening and NIPS and has compared which traditional screening using an appropriate intermediate risk the most suitable first-line screening test approach to NIPS. In view of the fact that the whole nation couldn't be covered by only one screening method because of the different detection ability and economic situation among different regions of China, our study offer clinicians clues to take a right choice.

Limitation {#Sec7}
==========

This study was limited to a public health system perspective across the duration of strategies of screening and diagnosis for fetal Down syndrome. The incidence of Down syndrome was biased among the groups, because an unknown proportion of fetuses might miscarry without fetal tissue diagnosis.

Materials and Methods {#Sec8}
=====================

Study design {#Sec9}
------------

This was a retrospective analysis of singleton pregnant women underwent combined first-trimester screening and quadruple screening, triple screening, double screening of second trimester. We collected and analyzed the results of combined first-trimester screening and the three screening tests of second trimester and there pregnancy outcomes, then we analyzed the performance of the four traditional screening tests. On this basis, it was assumed that the detection rate and false positive rate of NIPS were consistent with those reported, that meant detection rate of 99.5% and false positive of 0.5%^[@CR4]^. The uptake rates of NIPS and invasive prenatal diagnosis were assumed to be 100%. The 9 contingent models were combined by high risk cut-offs of 1:50, 1:100, 1:270 and intermediate risk cut-offs of 1:1000, 1:1500 and 1:2000. And then, analyzed the cost and performance of various screening models when adopted to contingent screening model at different cut-offs, Fig. [1](#Fig1){ref-type="fig"}.Figure 1Contingent screening model.

This study was conducted at Prenatal Diagnosis Center of West China Second University Hospital from January 2011 to December 2017. The study has been approved by the Institutional Ethics Committee of Sichuan University and all participants signed written informed consent prior to the test. The research was conducted in accordance with the relevant guidelines and clinical norms^[@CR29],[@CR30]^, the details were as flows. The inclusion criteria were a maternal age of 16 years or older, pregnancy with a singleton live fetus, and the gestational age of 11 weeks through 13 weeks 6 days in the first trimester, 15 weeks through 20 weeks 6 days in the second trimester. Women were excluded from the study if they had a family history of chromosomal abnormalities or congenital malformations, medical and surgical diseases during pregnancy, twins or multiple pregnancies, and one of the twins disappearing. Fetal chromosome status was determined by amniocentesis; or by tissue sampling in cases of spontaneous pregnancy loss, pregnancy termination, or stillbirth; or by telephone follow-up results of pregnant women who did not receive amniocentesis^[@CR30]^. The pregnant women were followed up by telephone six months after the pre delivery period to inquire about the pregnancy outcome and whether the fetus or newborn was normal^[@CR30]^, cross-linked with the Sichuan Prenatal Diagnosis Information Network.

Traditional screening {#Sec10}
---------------------

The combined first-trimester screening risk was calculated from measurements of nuchal translucency and two serum markers, pregnancy-associated plasma protein A (PAPP-A) and the free beta subunit of human chorionic gonadotropin (fβhCG), together with maternal age. The second trimester risk of quadruple screening was calculated from measurements of serum alpha-fetoprotein(AFP), the free beta subunit of human chorionic gonadotropin (fβhCG), unconjugated estriol and inhibin A, together with maternal age. The second trimester risk of triple screening was calculated from measurements of serum alpha-fetoprotein(AFP), the free beta subunit of human chorionic gonadotropin (fβhCG) and inhibin A, together with maternal age. The second-trimester risk of double screening was calculated from measurements of serum alpha-fetoprotein(AFP) and the free beta subunit of human chorionic gonadotropin (fβhCG), together with maternal age^[@CR31]^.

Measurements of biochemical markers were converted into multiples of the median (MoM) for gestational age, adjusted for maternal weight, insulin-dependent diabetes mellitus, status of smoking and race. Biochemical markers MoM values were center-specific. The risk of fetal Down syndrome was estimated by multiplying the maternal age-specific odds of the live birth of an infant affected by Down syndrome by the likelihood ratio obtained from the overlapping Gaussian distributions of affected and unaffected pregnancies.

Detection of serum alpha-fetoprotein (AFP), the free beta subunit of human chorionic gonadotropin (fbhCG), unconjugated estriol and pregnancy-associated plasma protein A(PAPP-A) by using reagents and instruments of Perkin Elmer (USA). Detection of inhibin A by using reagents and instruments of Beckman Coulter (USA). Using Lifecycle (Perkin Elmer, USA) to calculate risk of combined first-trimester screening and double screening and use Prenatal Screening Software (TCSoft,China) to calculate risk of quadruple screening and triple screening.

Cost of health service {#Sec11}
----------------------

A cost-effectiveness analysis was designed to evaluate contingent screening model in a retrospective traditional screening tests. In this contingent strategy, the follow-up to high risk further screening using amniocentesis and the follow-up to intermediate risk further screening using NIPS. As a result, the capability of intermediate risk will be reduced by 0.5% since the detection rate of NIPS screening is not 100% but rather 99.5%^[@CR4]^. In China, the price of health services was obtained based on the charges set by the local government. This study treated the price of health service as cost because it was paid by the medical insurance and pregnant women. The cost comes from actual charge price and references^[@CR32]--[@CR34]^.

Direct medical costs included the costs of NIPS, traditional screening tests, amniocentesis, and social costs of missed detection for DS. Direct nonmedical costs and non-direct costs were not included in this study. Costs in Chinese yuan were converted into USD at the average of 2015--2017 exchange rate of 6.50 yuan= USD 1.00, Table [5](#Tab5){ref-type="table"}.Table 5The cost of health service.ItemsCost(USD)CFTS^a^47double screening23triple screening35quadruple screening46NIPS369invasive diagnostic test^b^385missed detection for DS184615^a^The cost of combined first-trimester screening included measurements of PAPPA, freeβhCG and nuchal translucency; ^b^The cost of invasive diagnostic test included amniocentesis and analysis of fetal karyotype.

Statistical analysis {#Sec12}
--------------------

Descriptive data were presented as median (interquartile range (IQR)) for continuous variables and as n (%) for categorical variables. Comparisons between groups were performed using Kruskal-Wallis H test or Fisher's exact test for categorical variables. The statistical software package SPSS 23.0 (SPSS Inc., Chicago, IL, USA) was used for data analyses.
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